CAS No. 1826843-81-5 (ADC)
Batch:
Purity:
Chemical Structure
Check the
Trastuzumab-deruxtecan (DS-8201a, T-DXd)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
| CAS Number | 1826843-81-5 (ADC) | |
|---|---|---|
| Molecular Formula |
N/A |
|
| Molecular Weight (MW) | 153000 |
Trastuzumab deruxtecan (DS-8201a, T-DXd) is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2). Upon target binding and receptor endocytosis, its enzymatically cleavable linker releases a potent topoisomerase I inhibitor payload that stabilizes topoisomerase I-DNA complexes. This inhibition causes double-stranded DNA damage, triggering apoptosis and cell cycle arrest while exerting a bystander killing effect on neighboring tumor cells. [1][2]
|
Concentration
Volume
Mass
|
|---|
Batch:
All in vitro solubility values are batch-tested experimental data (non-literature values).
| Solvent | Solubility & Note |
|---|
Q: Why does a DMSO stock precipitate in media/saline?
A: It is caused by unheated aqueous media (supersaturation), local solvent shock, or incorrect mixing sequence.
How to fix it?
- Preheat media/saline to 37°C.
- Mix rapidly (pipette/vortex) upon addition.
- For complex mixes, always add the aqueous phase last.
- Re-dissolve minor precipitates with a 37°C water bath and sonication (≤30 min).
- Trastuzumab-deruxtecan (DS-8201a, T-DXd) Clinical Trials
- Trastuzumab-deruxtecan (DS-8201a, T-DXd) Stock Solution
- Trastuzumab-deruxtecan (DS-8201a, T-DXd) Storage
- Trastuzumab-deruxtecan (DS-8201a, T-DXd) Stability
- Trastuzumab-deruxtecan (DS-8201a, T-DXd) Molecular Weight
- Trastuzumab-deruxtecan (DS-8201a, T-DXd) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.